title: Effects of maternal symptom ratings and other clinical features on short-term treatment response to OROS methylphenidate in children and adolescents with ADHD in a naturalistic clinical setting.
abstract: OBJECTIVE
  To investigate the effect of Attention Deficit Hyperactivity Disorder (ADHD), antisocial behavior and anxiety/depression ratings of mothers, and child and adolescents' age, gender, ADHD subtype, and comorbidity on one-month drug treatment response to OROS methylphenidate in ADHD in a naturalistic setting.
  
  
  METHODS
  The analyses included 223 subjects (191 boys, 32 girls; age 6-15 years, mean: 9.4) treated with OROS methylphenidate (18-72 mg/day, mean: 31 mg/d; 0.4-1.4 mg/kg/d) for one-month. Treatment response was defined as larger than 25% or more decrease in pre-treatment the Conners Parent Rating Scale (CPRS) or the Conners Teacher Rating Scale (CTRS) total scores and the Clinical Global Impression improvement with drug treatment 3 (minimally improved) or higher. Maternal ADHD, antisocial behavior and anxiety/depression ratings were obtained by the Adult Self Rating (ASR). Logistic regression analyses were computed in order to calculate the effects of gender; age; ADHD subtype; comorbid anxiety disorder, learning disorder, oppositional defiant/conduct disorder; maternal ASR Anxiety/Depression, ADHD and Antisocial scores.
  
  
  RESULTS
  35.2% of subjects had statistically significant 25% or more decrease in pretreatment CPRS total scores and 38.6% of subjects had statistically significant 25% or more decrease in pretreatment CTRS total scores. The subjects with comorbid anxiety disorder had the poorest drug response. Maternal self-reported antisocial and anxiety/depressive symptomatology were statistically significantly associated with worse response to treatment in terms of CPRS (respectively, OR=0.83, 95% CI: 0.75-0.92, p<0.01; OR=0.95, 95% CI: 0.9-0.99, p<0.05) and CTRS total scores (OR=0.9, 95% CI: 0.82-0.99, OR=0.95, 95% CI: 0.91-1, p<0.05). Baseline rating scores were also important predictors of drug treatment response. Effects of age, gender and maternal ADHD were not statistically significant.
  
  
  CONCLUSIONS
  ADHD children and adolescents with comorbid anxiety disorders and those whose mothers have more self-reports of antisocial and depressive symptoms showed less favorable short-term response to OROS-MPH. These subjects may require further attention and additional interventions to augment treatment with OROS methylphenidate.
authors.affiliation: Yenimahalle Research and Training Hospital, Department of Child and Adolescent Psychiatry, Ankara, Turkey.
authors.forename: Esra Cop
authors.initials: EC
authors.lastname: Tasgin
authors.affiliation: Ankara University School of Medicine, Department of Child and Adolescent Psychiatry, Ankara, Turkey.
authors.forename: Ozgur
authors.initials: O
authors.lastname: Oner
authors.affiliation: Turgut Ozal University School of Medicine, Department of Child and Adolescent Psychiatry, Ankara, Turkey.
authors.forename: Pinar
authors.initials: P
authors.lastname: Yurtbasi
authors.affiliation: Harvard Medical School, Children's Hospital, Boston, MA, USA.
authors.forename: Kerim
authors.initials: K
authors.lastname: Munir
keywords: Attention Deficit Hyperactivity Disorder; OROS Methylphenidate; moderators; short-term treatment